(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, UTRECHT, Netherlands & BOSTON, Mass. US, 02 December 2022) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology ...
A new study published in Cell Press reveals critical insights into the role of gamma-delta T cells across 33 cancer types, shedding light on their potential as clinical biomarkers and therapeutic ...
TAMPA, Fla. (Oct. 4, 2024) — A new study published in Cell Press reveals critical insights into the role of gamma-delta T cells across 33 cancer types, shedding light on their potential as clinical ...
Gilead’s Kite Pharma has snagged an option to buy gamma delta T-cell receptor (TCR) startup Gadeta. The deal sees Kite take a stake in Gadeta and commit to milestones tied to the progress of oncology ...
New multi-program collaboration to develop allogeneic TCR-T/CAR-T programs brings together Immatics’ allogeneic gamma delta T cell therapy platform ACTallo® with Bristol Myers Squibb’s technologies ...
Agreement combines Gadeta’s gamma delta target and TCR identification expertise with Immunocore’s TCR bispecific engineering, development and commercialization capabilities to develop gamma delta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results